Inventiva S.A.
IVEVF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$751.18M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $751.18 Million |
|---|---|
| Enterprise Value | $651.75 Million |
| Earnings per Share | $-1.9 |
| Beta | 0.91 |
| Outstanding Shares | 273,582,870 |
Return
| Return on Equity | -946.81% |
|---|---|
| Return on Assets | -222.38% |
| Return on Invested Capital | -234.76% |
Valuation & Multiples
| P/E Ratio | -5.77 |
|---|---|
| PEG | 9.63 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 60.4 |
| Enterprise Value to EBIT | -1.49 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 1.13 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 28, 2026
EPS Estimate
$-0.42
Consensus analyst estimateRevenue Estimate
$2.86 M
Consensus analyst estimateNext Earnings Call
Expected Date
March 31, 2027
EPS Estimate
$-0.33
Consensus analyst estimateRevenue Estimate
$4.65 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Inventiva
77 employees
CEO: Frederic Cren
Inventiva S.A. is a clinical-stage biopharmaceutical firm dedicated to developing oral small molecule therapies. Its primary therapeutic focus areas include non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various o...